Pharmacotherapy for Friedreich ataxia (Q37423316)

20 August 2017

1 reference

title

Pharmacotherapy for Friedreich ataxia (English)

1 reference

20 August 2017

0 references

1 reference

Amy Y Tsou

1

1 reference

20 August 2017

Lisa S Friedman

series ordinal

2

1 reference

20 August 2017

Robert B Wilson

series ordinal

3

1 reference

20 August 2017

David R Lynch

series ordinal

4

1 reference

20 August 2017

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

23

1 reference

20 August 2017

3

1 reference

20 August 2017

213-223

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200923030-00003

20 August 2017

0 references

cites work

Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923030-00003

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923030-00003

Idebenone for treatment of Friedreich's ataxia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923030-00003

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200923030-00003

Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants.

21 January 2018

1 reference

12 December 2020

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

12 December 2020

Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy

1 reference

12 December 2020

Molecular pathogenesis of Friedreich ataxia

1 reference

12 December 2020

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

1 reference

12 December 2020

DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia

1 reference

12 December 2020

Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells

1 reference

12 December 2020

Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues

1 reference

12 December 2020

DNA triplexes and Friedreich ataxia

1 reference

12 December 2020

Pharmaceutical erythropoietin use in patients with cancer: is it time to abandon ship or just drop anchor?

1 reference

12 December 2020

Idebenone - monograph

1 reference

12 December 2020

Rational selection of small molecules that increase transcription through the GAA repeats found in Friedreich's ataxia.

1 reference

12 December 2020

Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes

1 reference

12 December 2020

The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins.

1 reference

12 December 2020

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

1 reference

12 December 2020

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

1 reference

12 December 2020

Idebenone in patients with Friedreich ataxia

1 reference

12 December 2020

Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes

1 reference

12 December 2020

Frataxin expression rescues mitochondrial dysfunctions in FRDA cells

1 reference

12 December 2020

High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia

1 reference

12 December 2020

Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features

1 reference

12 December 2020

The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia.

1 reference

12 December 2020

Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature

1 reference

12 December 2020

Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools

1 reference

12 December 2020

Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report

1 reference

12 December 2020

Safety, Tolerability, and Pharmacokinetics of High-Dose Idebenone in Patients With Friedreich Ataxia

1 reference

12 December 2020

Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia

1 reference

12 December 2020

Broadened Friedreich's ataxia phenotype after gene cloning. Minimal GAA expansion causes late-onset spastic ataxia

1 reference

12 December 2020

Performance measures in Friedreich ataxia: potential utility as clinical outcome tools

1 reference

12 December 2020

Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia

1 reference

12 December 2020

Biochemical study of idebenone effect on mitochondrial metabolism of yeast

1 reference

12 December 2020

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

1 reference

12 December 2020

Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up

1 reference

12 December 2020

Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up

1 reference

12 December 2020

Prevention of mitochondrial oxidative damage using targeted antioxidants

1 reference

12 December 2020

MitoQ--a mitochondria-targeted antioxidant.

1 reference

12 December 2020

Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia

1 reference

12 December 2020

Functional studies of frataxin.

1 reference

12 December 2020

Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin

1 reference

12 December 2020

The use of antioxidants in Friedreich's ataxia treatment

1 reference

12 December 2020

Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits

1 reference

12 December 2020

Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitro

1 reference

12 December 2020

Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion

1 reference

12 December 2020

Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy

1 reference

12 December 2020

Recombinant human erythropoietin: effects on frataxin expression in vitro

1 reference

12 December 2020

Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study

1 reference

12 December 2020

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

12 December 2020

Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia

1 reference

12 December 2020

Friedreich's ataxia: idebenone treatment in early stage patients

1 reference

12 December 2020

Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia

1 reference

12 December 2020

Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis

1 reference

12 December 2020

Iron dysregulation in Friedreich ataxia

1 reference

12 December 2020

Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis.

1 reference

12 December 2020

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

1 reference

12 December 2020

Measuring Friedreich ataxia: complementary features of examination and performance measures

1 reference

12 December 2020

Does erythropoietin have a dark side? Epo signaling and cancer cells

1 reference

12 December 2020

Effects of idebenone and related compounds on respiratory activities of brain mitochondria, and on lipid peroxidation of their membranes

1 reference

12 December 2020

Idebenone: a new antioxidant - Part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants

1 reference

12 December 2020

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

1 reference

12 December 2020

Selective iron chelation in Friedreich ataxia: biologic and clinical implications.

1 reference

12 December 2020

Frataxin point mutations in two patients with Friedreich's ataxia and unusual clinical features

1 reference

12 December 2020

Electroconvulsive therapy and Friedreich's ataxia

1 reference

12 December 2020

Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion

1 reference

12 December 2020

Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation

1 reference

12 December 2020

Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring

1 reference

12 December 2020

Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments.

1 reference

12 December 2020

Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat

1 reference

12 December 2020

The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits

1 reference

12 December 2020

Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties

1 reference

12 December 2020

Antioxidant use in Friedreich ataxia

1 reference

12 December 2020

Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity

1 reference

12 December 2020

10.2165/00023210-200923030-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference